Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has received supplemental approvals for the BRAF inhibitor Braftovi (encorafenib), and the MEK inhibitor Mektovi (binimetinib), when used in combination, in Japan for two new indications.
These indications are unresectable thyroid cancer with a BRAF mutation that has progressed following chemotherapy, and unresectable anaplastic thyroid cancer with a BRAF mutation.
Approvals are based on the results of a Phase II study, conducted in Japan in 22 patients with unresectable BRAF-mutant thyroid cancer, including five with anaplastic thyroid cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze